US 12,410,400 B2Granted

Methods for generating mimetic innate immune cells from pluripotent stem cells

AssigneeAgency for Science, Technology and Research

InventorsJieming Zeng, Shu Wang

Life of this patent

Estimating the term…

Loading patent…

Abstract

Human pluripotent stem cells (hPSCs), especially induced pluripotent stem cells (iPSCs) provide a promising starting material to produce mimetic innate immune cells such as natural killer (NK) cells and γδ T-cells for cancer immunotherapy. To facilitate consistent mass production, an overall manufacturing scheme to make mimetic innate immune cells from hPSCs was designed and demonstrated. Particularly, a robust protocol to differentiate hPSCs into NK cells or γδ T-cells through sequential hematopoietic differentiation on stromal cell line deficient in expressing M-CSF and lymphoid commitment on stromal cell line deficient in expressing M-CSF ectopically expressing DLL1 without employing CD34+ cell enrichment and spin embryoid body formation is established. Using this two-stage protocol, the generation of functional mimetic NK cells and functional mimetic γδ NKT-cells was demonstrated from hPSCs, including hESCs, peripheral blood cell-derived iPSCs (PBC-iPSCs). non-T cell-derived iPSCs or γδ T cell-derived iPSCs and the use of these mimetic innate immune cells in killing cancer cells.

Claims6

Dependent claims

A method of generating gamma-delta natural killer T cells (γδ NKT cells), the method comprising:

(a) expanding γδ T cells of human peripheral blood cells in PBMC culture medium containing an amino-bisphosphonate and interleukin 2 (IL2);
(b) transducing the expanded γδ T cells with reprogramming transcription factors to generate induced pluripotent stem cells (iPSCs);
(c) screening the TCRG and TCRD gene configuration of the iPSCs to identify γδ T cell-derived iPSCs;
(d) co-culturing γδ T cell-derived iPSCs with a stromal cell line deficient in expressing macrophage colony stimulating factor (M-CSF) to generate innate immune cell progenitors;
(e) co-culturing the innate immune cell progenitors with a stromal cell line deficient in expressing M-CSF and ectopically expressing Notch ligand, Delta like 1 (DLL1) in a media comprising stem cell factor (SCF), Fins-related tyrosine kinase 3 ligand (FLT3L), interleukin 7 (IL7) and interleukin 15 (IL15) to generate differentiated gamma-delta NKT cells;
(f) passaging the differentiated gamma-delta NKT cells weekly for 3 to 5 weeks to obtain gamma-delta NKT cells expressing gamma-delta TCRs (γδ TCRs);
and
(g) detecting the expression profile of the gamma-delta NKT cells obtained in step (f);
wherein the γδ NKT cells expressing gamma-delta TCRs (γδ TCRs), express NKp30 in 99% of the cells, NKp44 in 99% of the cells, NKp46 in 97% of the cells, NKG2D in 84% of the cells, DNAM-1 in 97% of the cells, TRAIL in 89% of the cells, and NKG2A/CD94 in 83% of the cells in combination with expression of at least any one of CD56, CD16, FASL and less than 5% expression of killer cell immunoglobulin-like receptors (KIR) are γδ NKT cells.

6 more elements

Dependencies are inferred from the claim text.